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Patients with rheumatoid arthritis (RA) suffer from pain and joint disability. The transient
receptor potential ankyrin 1 (TRPA1) channel expressed on sensory neurones and non-
neuronal cells mediates pain transduction and inflammation and it has been implicated in
RA. However, there is little information on the contribution of TRPA1 for human disease.
Here, we investigated the expression of TRPA1 on peripheral blood leukocytes and the
circulating levels of its endogenous activators 4-hydroxynonenal (4-HNE) and hydrogen
peroxide (H2O2) in RA patients treated or not with the anti-rheumatic leflunomide (LFN)
or the anti-TNFα adalimumab (ADA). We also assessed whether TRPA1 expression
correlates with joint pain and disability, in addition to the immune changes in RA. TRPA1
expression on peripheral blood leukocytes correlated with pain severity and disability.
TRPA1 levels on these cells were associated with the numbers of polymorphonuclear
and the activation of CD14+ cells. No correlations were found between the lymphocyte
population and TRPA1 expression, pain or disability. Patients recently diagnosed with
RA expressed increased levels of TRPA1 on their leukocytes whilst treatment with
either LFN or ADA down-regulated this receptor probably by reducing the numbers of
polymorphonuclears and the activation of CD14+ cells. We suggest that the activation
levels of CD14+ cells, the numbers of PMNs in the peripheral blood and the expression
of TRPA1 on peripheral blood leukocytes correlate with RA progression, affecting joint
pain sensitivity and loss of function.
Keywords: TRPA1, peripheral blood leukocytes, rheumatoid arthritis, polymorphonuclear cells, CD14+ cell
activation
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease that
affects approximately 1% of the population worldwide. Pain and
loss of joint function are hallmarks of RA. It leads to diminished
quality of life and increased burden on national health systems.
Whilst non-steroidal and steroidal drugs have been used for pain
management, RA treatment consists of disease-modifying anti-
rheumatic drugs (DMARDs) and biologicals which do not always
halt disease progression.
The transient receptor potential ankyrin 1 (TRPA1) is a
member of the transient receptor potential (TRP) family,
expressed on sensory neurones, in additional to non-
neuronal cells (for review see: Fernandes et al., 2012; Chen
and Hackos, 2015). Activated by endogenously produced
inflammatory mediators such as the oxidative stress products
4-hydroxynonenal (4-HNE; Trevisani et al., 2007) and
hydrogen peroxide (H2O2; Andersson et al., 2008; Bessac
et al., 2008), TRPA1 has been implicated in pain transduction
and inflammation (for review see: Fernandes et al., 2012; Chen
and Hackos, 2015). Since the discovery of TRPA1, evidence has
suggested that its functional expression on sensory neurones
innervating the joints and non-neuronal cells composing
the joints such as synoviocytes (Kochukov et al., 2006) and
chondrocytes (Nummenmaa et al., 2016) may contribute to RA
progression and the associated pain. Recently, functional TRPA1
was also found on immune cells (Billeter et al., 2015; Bertin
et al., 2016; Mendes et al., 2016) that are known to play a role
in RA. It is possible thus, that TRPA1 expression and activation
on these cells further amplify inflammation as they migrate in
to the joints during reactive RA. Although compelling, most of
the evidence arises from animal models, with little known role in
human disease, especially on how TRPA1 expression influences
components of the immune response in RA.
Transient receptor potential ankyrin 1 expression on
peripheral blood leukocytes has been linked to pain sensitivity in
neuropathic patients (Sukenaga et al., 2016). We hypothesized
that TRPA1 is up-regulated on peripheral blood leukocytes in
RA and that this is associated with increased joint pain and
reduced life quality. Therefore, we investigated the expression of
TRPA1 on peripheral blood leukocytes and the circulating levels
of 4-HNE and H2O2 in RA patients treated or not with either
the DMARD leflunomide (LFN) or the anti-TNFα adalimumab
(ADA). We also assessed whether TRPA1 expression correlates
with joint pain and disability, in addition to the immune changes
in RA.
MATERIALS AND METHODS
Patients
A total of 40 patients (men and women) aged ≥ 30 years and
clinically diagnosed with RA, were recruited for participation in
the study. Patients included those who have just been diagnosed
with RA but naïve for DMARDs and biologicals (n= 10); patients
under LFN (20 mg/day, per os, n = 15) and patients under
biological (ADA; 40 mg every 2 weeks, subcutaneously, n = 15)
therapy for at least 8-months and less than 12-months. Patients
presented a score ≥ 6 on the 2010 ACR-EULAR Classification
Criteria For RA as previously detailed (Aletaha et al., 2010).
Healthy subjects (n = 15) were used as controls and included
those who had no history of recent infections, malignancy or
other autoimmune diseases and no present or previous use of
DMARDs, biologicals or experimental drugs. All individuals
were assessed for pain level and disability by the Stanford
Health Assessment Questionnaire (HAQ; for review see: Bruce
and Fries, 2003). Accordingly, disability was evaluated by the
HAQ-disability index which assesses the patient’s difficulty in
performing his/her usual activities. Pain levels were determined
through the visual analog scale (VAS), in which the patient
indicates in a scale from 0 to 100, how much pain he/she felt
in the past week (0- indicates no pain and 100-indicates severe
pain). Ten millilitres (ml) of peripheral blood were collected from
each patient for separation of plasma, serum and peripheral blood
leukocytes. The study was reviewed and approved by the Human
Research Ethics Committee of the Universidade CEUMA and
was performed in compliance with the Declaration of Helsinki.
A written informed consent was obtained from each participant.
Serum Rheumatoid Factor
For rheumatoid factor quantification we used a rheumatoid factor
particle-enhanced immunoturbidimetric method (RF II- Tina
quant RF II, COBAS) in a COBAS INTEGRA 400 analyzer
(Roche Diagnostics). For this, samples were initially diluted
(1:5) and then, serial dilutions were prepared automatically (up
to 1:128). Samples (50 µl) were incubated with latex particles
coated with monoclonal anti-rheumatoid factor antibodies.
Agglutination, denoted by formation of aggregates in positive
samples, was determined turbidimetrically. Results are expressed
as international units (IU) per litre (l) of sample.
Serum C-Reactive Protein
For C-reactive protein quantification we used a CRP particle-
enhanced immunoturbidimetric method (CRPL3- C Reactive
Protein Gen 3, COBAS) in a COBAS INTEGRA 400 analyzer
(Roche Diagnostics). For this, samples were initially diluted
(1:2) and then, serial dilutions were prepared automatically (up
to 1:128). Samples (50 µl) were incubated with latex particles
coated with monoclonal anti-C-reactive protein antibodies.
Agglutination, denoted by formation of aggregates in positive
samples, was determined turbidimetrically. Results are expressed
as milligrams (mg) per millilitre (ml) of sample.
Plasma 4-HNE Levels
Plasma samples were separated by centrifugation (15 min,
800 × g) and evaluated for 4-HNE content by using a
commercial OxiSelectTM HNE Adduct Competitive ELISA
Kit (Cell Biolabs, San Diego, CA, USA), according to the
manufacturer’s instructions. Results are expressed as levels of
4-HNE in micrograms (µg) per ml.
Plasma H2O2 Levels
H2O2 production in plasma samples was measured by using
a H2O2/peroxidase assay kit (Amplex Red H2O2/Peroxidase
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assay kit; Molecular Probes, Invitrogen, Brazil). The assay was
performed according to the manufacturer’s instructions. Briefly,
50 µl of plasma were incubated with 50 µl of a solution
containing NaPO4 0.05 M (pH 7.4), HRP 0.2 U/ml and Amplex
Red Reagent (10-acetyl-3,7-dihydroxyphenoxazine) 25.7 mg/ml,
for 2 h, at 37◦C. Samples incubated with NaPO4 0.05 M
only were used as controls. After incubation, the reaction was
read at 560 nm. After subtraction of background readings, the
absorbance in each sample was compared with that obtained
from a H2O2 (0–40 µM) standard curve. Results are expressed
as H2O2 levels in micromolar (µM).
Plasma TNFα Levels
The plasma levels of TNFα were evaluated by using a human
cytometric bead array (CBA) cytokine kit (BD Biosciences,
Brazil) according to the manufacturer’s instructions. Analysis
was performed on a Facscalibur cytometer flow cytometer (BD
Biosciences-Immunocytometry Systems). Results were calculated
in CBA FCAP Array software (BD Biosciences, Brazil) and are
expressed as pg/ml.
TRPA1 Expression on Peripheral Blood
Leukocytes
For analysis of human TRPA1 expression on peripheral blood
leukocytes, samples were prepared and assayed in a commercial
enzyme-linked immunosorbent assay kit, according to the
manufacturer’s instructions (Cloud-Clone Corp, Houston, TX,
USA). Briefly, samples were collected and the red blood cells
were lysed with Cell Lysis Buffer (BD Pharmingen, Brazil).
Total leukocytes were then separated by centrifugation (30 min,
800 × g), resuspended in ice-cold phosphate-buffered saline
(PBS) and ultrasonicated for four times. Cell lysates were
centrifuged (10 min, 800× g, 4◦C) to remove cell debris and kept
at −70◦C for further analysis. On the day of the experiments,
samples were defrosted and assayed. Results are expressed as
nanograms of TRPA1 per milligram of protein (ng/mg) in each
sample.
Flow Cytometry Analysis
For flow cytometry analysis, peripheral blood samples underwent
red blood cell lysis as previously described for the quantification
of TRPA1 on leukocytes. Single-cell suspensions were prepared
and cells were then stained with Trypan blue (Sigma–Aldrich,
Brazil) and assessed for viability in a haemocytometer. Cells
(5 × 106) were washed, resuspended in flow cytometry
buffer [(2% fetal calf serum (Invitrogen, Brazil) in phosphate
buffered saline-PBS (Sigma–Aldrich, Brazil)], and stained with
directly conjugated monoclonal antibodies (BD Biosciences
or eBiosciences, Brazil): anti-CD4 PE-Cy5 (clone RPA-T4),
anti-CD14 FITC (clone 61D3), anti-CD19 FITC (clone HIB19),
anti-CD25 PE (clone BC96; activation marker), anti-CD69
(clone FN50; activation marker), anti-CD127 FITC (clone
eBioRDR5; activation marker), anti-HLA-DR PE-Cy5 (clone
LN3). In order to discriminate regulatory T cells from activated
CD4+ T cells, gates were placed on CD4+CD25+CD127low
and CD4+CD25+CD127high cell populations, respectively.
Events were acquired on a BD Accuri C6 (BD Biosciences-
Immunocytometry Systems) and analyzed using FlowJo software
(Tree Star Inc.). Additionally, differential cell populations
[polymorphonuclear (PMNs) and mononuclear cells] were
identified by size and granularity through flow cytometry.
Results are expressed as well as number of cells per mm3, except
for HLA-DR, expressed as mean fluorescence.
Data Analysis
Data are represented as mean ± SD or median and interquartile
range (25–75th; IQR), depending on their distribution.
Accordingly, we used parametric (ANOVA followed by
Bonferroni’s test) or non-parametric (Kruskal–Wallis) tests to
determine the significance of differences between groups in the
HAQ-DI and VAS pain scale scores; TRPA1, 4-HNE, H2O2,
and TNFα levels; and leukocyte subpopulations. Correlations
between the different parameters were determined using
Spearman’s rho. Statistical analysis was undertaken using IBM
SPSS Statistics 20. p-values < 0.05 were considered statistically
significant.
RESULTS
Subject Characteristics
Data depicted on Table 1 shows that the arthritic population
primarily consisted of women (75%). Also, most of the recently
diagnosed arthritic patients (those receiving no specific treatment
with anti-rheumatic drugs, NST group) presented disease for
less than 10 years (80%) whilst 60% of the patients under
treatment with LFN and 80% of the patients under treatment with
ADA had disease symptoms for longer than 10 years. Swollen
joints were present in 90% of the recently diagnosed patients.
These patients also exhibited higher levels of C-reactive protein
and rheumatoid factor. This symptom was less noticeable in
those taking either LFN (33.3% of the patients) or ADA (20%
of the patients). The incidence of lumps and deformities was
higher in patients receiving LFN or ADA, in comparison with
patients recently diagnosed with RA. Nine women and six men
composed the population of healthy subjects, with an average age
of 39.6± 4.6 years.
TRPA1 Expression on Leukocytes
Correlates with Joint Pain and Disability
As shown in Figure 1, the NST group presented higher levels of
joint pain (VAS pain scale; Figure 1A) and increased disability
(HAQ disability index, HAQ-DI; Figure 1B) when compared
with healthy subjects and patients treated with either LFN or
ADA. Pain and disability levels correlated with TRPA1 expression
levels on leukocytes (r = 0.329 and r = 0.390; respectively;
p < 0.05; Figure 1D) as this receptor was markedly increased
(2.6-fold) in patients who had been recently diagnosed with RA
in comparison with those of healthy subjects and patients under
LFN or ADA therapy (Figure 1C). Healthy subjects and patients
taking LFN and ADA expressed ∼50% less TRPA1 on their
leukocytes than those of NST patients.
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Plasma 4-HNE, H2O2, and TNFα Levels
4-HNE and H2O2 levels were increased by 2.4- and 5.6-fold
in the NST group, respectively, in comparison with healthy
subjects (Figures 2A,B; p < 0.05). On the other hand, 4-HNE
levels did not differ between the arthritic groups (Figure 2A).
Analysis of H2O2 showed that patients under ADA but not LFN
treatment exhibited lower levels of this inflammatory mediator
in their plasma (35.9 ± 27.0%) in comparison with those of
the NST group (Figure 2B; p < 0.05). A correlation between
the circulating levels of 4-HNE and disability in the NST group
(r = 0.926; p < 0.05) was observed. Also, reduced joint pain
and disability were accompanied by reduced levels of H2O2
in patients taking ADA (Figure 2B). On the other hand, not
all samples presented detectable levels of TNFα. This cytokine
was detected in only 5 out of 10 NST patients, 13 out of 15
patients taking LFN, 10 out of 15 patients taking ADA and
11 out of 15 healthy subjects. No differences were observed
between the evaluated groups. Median and IQR values observed
for TNFα are as follows: healthy subject group: 1.54 (0.98–1.66),
NST group: 0.92 (0.66–4.82), RA patients under LFN treatment:
1.5 (0.63–5.37) and RA patients under ADA treatment: 0.88
(0.37–1.25). No correlations were found between TNFα levels
and pain or disability, and neither between this cytokine and
TRPA1 expression on whole peripheral blood leukocytes or the
phenotypic characteristics of leukocytes.
Correlation between the Number of
PMNs and the Activation of CD14+ Cells
with TRPA1 Expression
The numbers of total leukocytes, mononuclear and PMN
cells were analyzed. Total leukocyte and PMN numbers
(Figures 3A–C) were markedly reduced in LFN patients
(36.8 ± 30.1 and 43.1 ± 24.9%, respectively) in comparison
with the NST group. Also, PMN numbers were diminished
(34.8± 30.8%) in ADA patients (Figure 3C). No differences were
observed in the mononuclear cell numbers between the groups
(Figure 2B). Analysis of CD14+ cells showed that their numbers
do not differ between the groups (Figure 3D). The activation
of CD14+ cells, denoted by HLA-DR mean fluorescence, was
significantly increased (1.9–2.6-fold) in samples obtained from
NST patients in comparison to those of the other arthritic groups
and healthy subjects (Figure 3E). Additionally, a correlation
between the numbers of PMNs and TRPA1 expression (r= 0.476;
p < 0.05); and pain (r = 0.349; p < 0.05) was observed.
Evaluation of lymphocyte subpopulations (Table 2)
demonstrated an increase in the numbers of circulating CD4+
(T helper lymphocytes) CD8+ (T cytotoxic lymphocytes) and
CD19+ (B lymphocytes) cells including those activated (CD25+,
CD25+CD127high or CD69+) in the NST group comparison
with healthy subjects, however, this was not significant. LFN
diminished the numbers of CD4+, CD4+CD25+CD127low
and CD8+ cells (reduction of 55.6 ± 21.6%, 55.0 ± 27.0, and
57.4 ± 28.8%, respectively). The same patients presented with
52.9% less circulating CD4+CD25+CD127high cells than the NST
group. No differences were observed for the other parameters
between the tested groups.
No significant correlations were observed between TRPA1
expression and lymphocyte numbers and/or activation.
DISCUSSION
TRPA1 Expression on Peripheral Blood
Leukocytes Is Increased in RA Patients
Here, we show for the first time that TRPA1 protein expression on
peripheral blood leukocytes positively correlates with joint pain
TABLE 1 | Characteristics of the patients.
Variable Arthritic patients
NST LFN ADA
Gender (n◦ of patients/%) n◦(%) n◦(%) n◦(%)
Age [Mean (SD)] 40.5 (8.39) 54.60 (12.07) 54.87 (10.88)
Male 1 (10%) 04 (26.7) 05 (33.3)
Female 09 (90%) 11 (73.3) 10 (66.7)
Duration of disease (in years) n◦ (%) n◦ (%) n◦ (%)
<10 08 (80%) 06 (40%) 03 (20%)
10–19 02 (20%) 07 (46.7%) 05 (33.3%)
20–29 00 (0%) 02 (13.3%) 05 (33.3%)
>30 00 (0%) 00 (0%) 02 (13.4%)
Presence of swollen joints n◦ (%) n◦ (%) n (%)
Yes 09 (90%) 05 (33.3%) 03 (20%)
No 01 (10%) 10 (66.7%) 12 (80%)
Presence of lumps or deformities n◦ (%) n◦ (%) n◦ (%)
Yes 02 (20%) 07 (46.7%) 12 (80%)
No 08 (80%) 08 (53.3%) 03 (20%)
C-reactive protein, mg/l [Median (IQR)] [31.0 (11.8-78.8)] [1.1 (0.3-2.2)] [1.3 (0.1-2.6)]
Rheumatoid factor, IU/ml [Median (IQR) [160 (93.5-266.0)] [31 (9.3-96.0)] [20.0 (5.0-76.4)]
Continuous variables are expressed as median (25–75th percentile; IQR). Categorical variables are summarized as n (%).
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FIGURE 1 | (A) Visual analog scale (VAS) pain scale, (B) HAQ-DI, and (C) TRPA1 expression on peripheral blood leukocytes in patients with rheumatoid arthritis (RA)
treated or not with either leflunomide (LFN; n = 15) or adalimumab (ADA; n = 15), in comparison with patients recently diagnosed with RA but not yet receiving
specific treatment with anti-rheumatic drugs (NST group; n = 10) and healthy subjects (n = 15). Data are expressed as mean ± SD. (D) Scatter plot for TRPA1
correlation with VAS pain scale and HAQ-DI. ∗p < 0.05, differs from healthy subjects; #p < 0.05, differs from the NST group.
FIGURE 2 | Systemic (A) 4-HNE and (B) H2O2 levels in patients with RA treated or not with either leflunomide (LFN; n = 15) or adalimumab (ADA; n = 15), in
comparison with patients recently diagnosed with RA but not yet receiving specific treatment with anti-rheumatic drugs (NST group; n = 10) and healthy subjects
(n = 15). Data are expressed as mean ± SD. ∗p < 0.05, differs from healthy subjects; #p < 0.05, differs from the NST group.
and disability in RA patients. To the best of our knowledge, this
is the first study showing that patients recently diagnosed with RA
express increased levels of TRPA1 on their leukocytes and that the
treatment with either LFN or ADA down-regulates this receptor.
Transient receptor potential ankyrin 1 channels expressed
on neuronal tissues have been widely predicted as important
transducers of pain sensation (for review see: Chen and
Hackos, 2015). Recently, TRPA1 was found to contribute to
joint pain and inflammation in a murine model of chronic
arthritis induced by complete Freund’s adjuvant (Fernandes
et al., 2011; Horváth et al., 2016). The discovery of functional
TRPA1 on cells located in the joints such as synoviocytes and
chondrocytes (Kochukov et al., 2006; Nummenmaa et al., 2016),
in addition to its expression on immune cells (Billeter et al.,
2015; Bertin et al., 2016; Mendes et al., 2016) have unveiled
novel pathways on the peripheral modulation of pain. In a
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FIGURE 3 | Peripheral blood total (A), mononuclear (B), and polymorphonuclear (PMNs) (C) cells; CD14+ cells (D) and HLA-DR mean fluorescence intensity in
CD14+ cells (E) in patients with RA treated or not with either leflunomide (LFN; n = 15) or adalimumab (ADA; n = 15), in comparison with patients recently
diagnosed with RA but not yet receiving specific treatment with anti-rheumatic drugs (NST group; n = 10) and healthy subjects (n = 15). Data are expressed as
mean ± SD or median (25–75th percentile). ∗p < 0.05, differs from healthy subjects; #p < 0.05, differs from the NST group.
recent report, TRPA1 expression on peripheral blood leukocytes
was found to be associated with pain sensitivity (Sukenaga
et al., 2016). Indeed, patients with increased neuropathic
pain symptoms presented with lower TRPA1 mRNA levels
on their leukocytes. Similarly, Bell et al. (2014) showed that
individuals with lower pain thresholds express lower TRPA1
mRNA levels in peripheral tissues such as the skin. Here, we
show evidence on that TRPA1 protein expression is augmented
in RA patients with increased pain and disability. Although
both neuropathic and arthritic pain are of chronic nature,
the different results obtained in these studies may be due to
differences in TRPA1 quantification (mRNA × protein), length
of disease and immunological components underlying these
pathologies.
Here, TRPA1 expression was analyzed by an enzyme-
linked immunosorbent assay. Enzyme-linked immunosorbent
assays allow the simultaneous evaluation of many samples
to a given protein with high sensitivity, but their specificity
depends on assay conditions. Of note, their specificity may
be comparable to those of western blot analysis for the
detection of protein expression; however, results can differ
depending on the antigenic preparation used in the two assays
(Dittadi et al., 1993; Révélen et al., 2002; Liu et al., 2009).
Importantly, TRPA1 expression was previously shown to be
increased on leukocytes such as monocytes and lymphocytes
in other inflammatory conditions including in LPS challenge
and inflammatory bowel disease (Billeter et al., 2015; Bertin
et al., 2016). It is possible that once increased, TRPA1 expression
contributes to the progression or outcome of inflammatory
diseases.
4-HNE and H2O2 Levels Are Increased in
RA Patients
The endogenously produced oxidants 4-HNE and H2O2 are
suggested to play a role in RA, contributing to disease progression
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TABLE 2 | Peripheral blood leukocyte populations in healthy subjects and arthritic patients.
Leukocyte population(cells/mm3) Healthy subjects Arthritic patients
NST LFN ADA
CD4+ 309.9 ± 192.6 420.0 ± 326.2 186.5 ± 90.7# 501.0 ± 349.2
CD4+CD25+CD127high 32.7 (21.3–51.8) 42.0 (27.5–132.6) 19.8 (13.2–24.3)# 47.8 (16.7–100.5)
CD4+CD25+CD127low 33.6 ± 16.1 43.3 ± 30.5 19.5 ± 11.7# 51.2 ± 35.1
CD4+CD69+ 51.3 ± 33.0 93.8 ± 104.7 36.7 ± 24.6 75.8 ± 58.5
CD8+ 138.6 ± 63.3 254.9 ± 276.8 108.6 ± 73.3# 272.0 ± 237.4
CD8+CD69+ 23.0 ± 16.8 38.9 ± 33.8 17.1 ± 16.1 44.0 ± 47.3
CD19+ 33.6 (20.4–45.5) 60.2 (17.0–101.1) 38.3 (19.8–75.7) 103.4 (22.9–148.7)
CD19+CD69+ 8.5 ± 5.4 28.2 ± 34.8 17.5 ± 14.2 17.5 ± 19.2
Samples were obtained from patients with rheumatoid arthritis (RA) treated or not with either leflunomide (LFN; n = 15) or adalimumab (ADA; n = 15) and compared
with patients recently diagnosed with RA but not yet receiving specific treatment with anti-rheumatic drugs (NST group; n = 10) and healthy subjects (n = 15). Data are
expressed as mean ± SD. #p < 0.05, differs from the NST group. Variables are expressed as mean ± SD or median (25–75th percentile; IQR).
(Remans et al., 2005; Yin et al., 2015). Recently, H2O2 was
suggested to be critical to T cell differentiation (Abimannan
et al., 2016). Indeed, the circulating levels of reactive oxygen
species such as H2O2 and superoxide were recently found to
be strongly and positively correlated with RA symptoms and
disease activity markers (Khojah et al., 2016). Similarly, plasma
4-HNE levels are elevated in RA patients (Łuczaj et al., 2016).
Both 4-HNE and H2O2 have been suggested as biomarkers for
monitoring RA progression and are known activators of TRPA1
(Trevisani et al., 2007; Andersson et al., 2008; Bessac et al.,
2008).
Here, 4-HNE levels were raised in RA. No significant
differences were found in the 4-HNE levels between the arthritic
groups, although a correlation between the circulating levels of 4-
HNE and disability was observed in the NST group only. Our data
also show that arthritic patients presented higher levels of H2O2
in their plasma, and that this oxidant is reduced in RA patients
under ADA therapy.
Neither 4-HNE nor H2O2 were found to correlate with the
TRPA1 expression on peripheral blood leukocytes or pain. It is
possible that the ongoing oxidative stress may not affect TRPA1
expression on these cells, and thus, may not affect pain sensitivity
mediated by this channel in RA.
TNFα plays a central role in RA pathophysiology, mediating
bone resorption and joint pain and inflammation in RA, in
addition to contributing to extra-articular disease (for review
see: McInnes et al., 2016). Recent evidence indicates that
TRPA1 mediates TNFα-induced pain in vivo (Fernandes et al.,
2011), and that this cytokine enhances TRPA1 expression on
non-neuronal cells (El Karim et al., 2015). Therefore, we
assessed the circulating levels of TNFα in healthy subjects
and in RA patients. No differences were observed between
the groups. Of note, we were not able to detect circulating
TNFα in 50% of the samples obtained from NST patients.
Although being important for the transition of RA toward
chronicity, TNFα levels may peak during the maintenance of
established disease (McInnes et al., 2016). TNFα levels were
not correlated with any of the parameters assessed. This may
be related to the fact this cytokine was not detected in all
patients.
The Correlation between TRPA1
Expression on Peripheral Blood
Leukocytes and Pain and Disability in RA
Is Associated with the Numbers of PMN
and Activation of CD14+ Cells
Our data shows that the correlation between TRPA1 expression
on peripheral blood leukocytes, pain and disability in arthritic
patients is associated with the numbers of PMNs and with
the activation of CD14+ cells. Horváth et al. (2016) found
that TRPA1 ablation decreases neutrophil accumulation into
the joints of animals with arthritis. Also, TRPA1 was recently
shown to mediate the acute inflammatory responses mediated
by CD14+ expressing cells such as macrophages (Mendes
et al., 2016) and monocytes (Billeter et al., 2015). Additionally,
the functional expression of TRPA1 on CD4+ lymphocytes
was previously reported and the activation of this channel
was suggested to down-regulate T-cell mediated responses
in chronic inflammation (Bertin et al., 2016). However, we
did not observe any correlations between the circulating
lymphocyte subpopulations and TRPA1 expression or pain and
disability in arthritic patients. Also, no correlations were found
between lymphocyte subpopulations and the systemic levels
of 4-HNE and H2O2. It is possible though that lymphocytes
located in to the joints differently influence RA progression
as this receptor may suffer the influence of a plethora of
inflammatory molecules (i.e., oxidative stress products and
cytokines such as TNFα) released in higher levels in this
microenvironment.
We found that RA patients receiving either LFN or ADA
presented lower numbers of circulating PMNs and less activation
of CD14+ cells than those of the NST group. Both LFN and
ADA are able to directly suppress immune cell proliferation
and migration in to the joints. LFN is known to block T cell
proliferation by inhibiting dihydro-orotate dehydrogenase and
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the synthesis of pyrimidine (Fragoso and Brooks, 2015), and
to reduce the expression of adhesion molecules on peripheral
blood mononuclear cells and their migration in to the inflamed
synovia (Grisar et al., 2004). ADA was also shown to reduce
peripheral blood leukocyte (monocytes and PMNs) adhesion to
the endothelium (Ríos-Navarro et al., 2015). Inhibitory effects
on T cell proliferation via macrophage-dependent mechanisms
were also observed for ADA (Vos et al., 2011). Taking
these evidences in to account, it is possible to suggest that
in the NST group, infiltrating leukocytes expressing TRPA1
may contribute to exacerbate joint inflammation, a response
that may be attenuated in patients receiving anti-rheumatic
therapy.
In summary, our data demonstrates that TRPA1 expression
on peripheral blood leukocytes is increased in NST RA
patients and this is associated with higher numbers of
circulating neutrophils and increased CD14+ cell activation.
In turn, these changes affect pain and disability as TRPA1-
expressing leukocytes may migrate in to the joints during
reactive RA further amplifying inflammation. Finally, reduced
TRPA1 expression in patients treated with either LFN or
ADA is accompanied by reduction of the circulating PMN
population and decreased activation of CD14+ cells, thus
resulting in decreased pain and disability in RA. These
results suggest that the activation levels of CD14+ cells
and the numbers of PMNs in the peripheral blood is
associated with TRPA1 expression and this may impact RA
progression.
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